Assembly Biosciences Stock Total Asset
| ASMB Stock | USD 18.40 0.47 2.62% |
By evaluating key metrics such as revenue growth, profitability, cash flow trends, and balance sheet strength, investors can better assess Assembly Biosciences' long-term financial health and intrinsic value.
This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools. Assembly Biosciences Company Total Asset Analysis
Assembly Biosciences' Total Asset is everything that a business owns. It is the sum of current and long-term assets owned by a firm at a given time. These assets are listed on a balance sheet and typically valued based on their purchasing prices, not the current market value.
Current Assembly Biosciences Total Asset | 119.17 M |
Most of Assembly Biosciences' fundamental indicators, such as Total Asset, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Assembly Biosciences is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Total Asset is typically divided on the balance sheet on current asset and long-term asset. Long-term is the value of company property and other capital assets that are expected to be useable for more than one year. Long term assets are reported net of depreciation. On the other hand current assets are assets that are expected to be sold or converted to cash as part of normal business operation.
| Competition |
Based on the latest financial disclosure, Assembly Biosciences has a Total Asset of 119.17 M. This is 98.42% lower than that of the Biotechnology sector and 93.97% lower than that of the Health Care industry. The total asset for all United States stocks is 99.6% higher than that of the company.
Assembly Total Asset Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Assembly Biosciences' direct or indirect competition against its Total Asset to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Assembly Biosciences could also be used in its relative valuation, which is a method of valuing Assembly Biosciences by comparing valuation metrics of similar companies.Assembly Biosciences is currently under evaluation in total asset category among its peers.
Assembly Fundamentals
| Return On Equity | -1.34 | ||||
| Return On Asset | -0.25 | ||||
| Profit Margin | (1.24) % | ||||
| Operating Margin | (1.06) % | ||||
| Current Valuation | 52.52 M | ||||
| Shares Outstanding | 7.64 M | ||||
| Shares Owned By Insiders | 39.25 % | ||||
| Shares Owned By Institutions | 12.97 % | ||||
| Number Of Shares Shorted | 30.65 K | ||||
| Price To Earning | (10.58) X | ||||
| Price To Book | 5.18 X | ||||
| Price To Sales | 4.37 X | ||||
| Revenue | 28.52 M | ||||
| Gross Profit | (26.75 M) | ||||
| EBITDA | (45.42 M) | ||||
| Net Income | (40.18 M) | ||||
| Cash And Equivalents | 116.69 M | ||||
| Cash Per Share | 2.41 X | ||||
| Total Debt | 3.09 M | ||||
| Debt To Equity | 0.04 % | ||||
| Current Ratio | 8.31 X | ||||
| Book Value Per Share | 3.56 X | ||||
| Cash Flow From Operations | (51.12 M) | ||||
| Short Ratio | 0.72 X | ||||
| Earnings Per Share | (6.20) X | ||||
| Target Price | 30.0 | ||||
| Number Of Employees | 73 | ||||
| Beta | 0.63 | ||||
| Market Capitalization | 140.53 M | ||||
| Total Asset | 119.17 M | ||||
| Retained Earnings | (825.92 M) | ||||
| Working Capital | 67.7 M | ||||
| Current Asset | 68.37 M | ||||
| Current Liabilities | 3.4 M | ||||
| Net Asset | 119.17 M |
About Assembly Biosciences Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Assembly Biosciences's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Assembly Biosciences using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Assembly Biosciences based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Assembly Biosciences offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Assembly Biosciences' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Assembly Biosciences Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Assembly Biosciences Stock:Check out Assembly Biosciences Piotroski F Score and Assembly Biosciences Altman Z Score analysis. For information on how to trade Assembly Stock refer to our How to Trade Assembly Stock guide.You can also try the Portfolio File Import module to quickly import all of your third-party portfolios from your local drive in csv format.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Assembly Biosciences. If investors know Assembly will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Assembly Biosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Assembly Biosciences is measured differently than its book value, which is the value of Assembly that is recorded on the company's balance sheet. Investors also form their own opinion of Assembly Biosciences' value that differs from its market value or its book value, called intrinsic value, which is Assembly Biosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Assembly Biosciences' market value can be influenced by many factors that don't directly affect Assembly Biosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Assembly Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Assembly Biosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Assembly Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.